# triumvira.com

> AI-optimized mirror of triumvira.com containing 187 pages totalling 73,242 words of clean markdown content, structured data, and semantic HTML. Original source: https://triumvira.com. Last updated: 2026-07-26T07:07:36.273Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Home - Triumvira Immunologics | Engineered T Cell Therapies](/content/site-root.html) (231 words)

## Articles & Blog Posts

- [SITC Poster 2022 - GUCY2C v7.cdr](/content/wp-content/uploads/2022/11/sitc-poster-2022-gucy2c-pdf.html) (1,173 words)
- [SITC 2023 Clinical Poster.cdr](/content/wp-content/uploads/2023/11/triumvira-sitc-cl-654-pdf.html) (958 words)
- [ESMO Poster 2022 Draft 10.cdr](/content/wp-content/uploads/2022/09/triumvira-esmo-poster-sept-2022-pdf.html) (1,019 words)
- [SITC Poster 2022 Clinical Poster.cdr](/content/wp-content/uploads/2022/11/sitc-poster-2022-clinical-poster-pdf.html) (880 words)
- [SITC Poster 2022 - MoA_CWH.cdr](/content/wp-content/uploads/2022/11/sitc-poster-2022-moa-pdf.html) (921 words)
- [SITC Poster 2022 - CLND18.2 v7.cdr](/content/wp-content/uploads/2022/11/sitc-poster-2022-clnd18-2-pdf.html) (1,017 words)
- [Page not found - Triumvira Immunologics | Engineered T Cell Therapies](/content/technology-science/tac-car-t-tcr-differences/index.html) (28 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2022/08/triumvira-aacr-march-22-poster-pdf.html) (712 words)
- [AACR Poster 2023 GDT cells v9.cdr](/content/wp-content/uploads/2023/04/triumvira-aacr-poster-2023-gdt-cells-final-pdf.html) (911 words)
- [ASCO GI 2025 poster.cdr](/content/wp-content/uploads/2025/01/asco-gi-2025-poster-pdf.html) (1,035 words)
- [SITC Poster 2023 Allo_final.cdr](/content/wp-content/uploads/2023/11/triumvira-sitc-rd-400-pdf.html) (1,374 words)
- [Poster SITC (2023).cdr](/content/wp-content/uploads/2023/11/triumvira-sitc-cl-738-pdf.html) (855 words)
- [Page not found - Triumvira Immunologics | Engineered T Cell Therapies](/content/programs/pipeline/index.html) (24 words)
- [Page not found - Triumvira Immunologics | Engineered T Cell Therapies](/content/press-releases/index.html) (28 words)
- [SITC 2024 poster.cdr](/content/wp-content/uploads/2024/11/triumvira-claudin-18-2-sitc-2024-pdf.html) (1,108 words)
- [AACR Poster 2023 Clinical Poster.cdr](/content/wp-content/uploads/2023/04/triumvira-aacr-poster-2023-investigating-safety-final-pdf.html) (1,085 words)
- [AACR Poster 2023 PT Derived Product v2.cdr](/content/wp-content/uploads/2023/04/triumvira-aacr-poster-2023-pt-derived-product-final-pdf.html) (920 words)
- [patient-derived-tac01-her2-tac-t-cells-produced-in-cocoon-platform-is-highly-functional-in-models-of-solid-tumors.html](/content/patient-derived-tac01-her2-tac-t-cells-produced-in-cocoon-platform-is-highly-functional-in-models-of-solid-tumors.html) (126 words)
- [a-phase-i-ii-trial-investigating-safety-and-efficacy-of-autologous-tac01-her2-in-relapsed-or-refractory-solid-tumors.html](/content/a-phase-i-ii-trial-investigating-safety-and-efficacy-of-autologous-tac01-her2-in-relapsed-or-refractory-solid-tumors.html) (126 words)
- [Privacy Policy - Triumvira Immunologics | Engineered T Cell Therapies](/content/privacy-policy/index.html): This Privacy & Legal Policy was last updated April 23, 2018 Our Policy: Welcome to the website (the “Website”) of Triumvira Immunologics Inc. and its subsidiaries and affiliates (“Triumvira Immunologics Inc.”, “we”, “us” and/or “our”). This Website is owned and operated by Triumvira Immunologics Inc. and has been created to provide information about our company […] (2,433 words)
- [biotech-cfos-sharpen-financing-tactics-for-lean-times.html](/content/biotech-cfos-sharpen-financing-tactics-for-lean-times.html) (134 words)
- [SITC Poster 2023 - GUCY2C Final.cdr](/content/wp-content/uploads/2023/11/triumvira-sitc-rd-347-1-pdf.html) (458 words)
- [Page not found - Triumvira Immunologics | Engineered T Cell Therapies](/content/news-resources/press-releases/index.html) (28 words)
- [SITC Poster 2023 MoA_v3.cdr](/content/wp-content/uploads/2023/11/triumvira-sitc-rd-372-pdf.html) (599 words)
- [Terms of Use - Triumvira Immunologics | Engineered T Cell Therapies](/content/tac-terms-of-use/index.html): 1. Acceptance of the Terms and Conditions. 1.1 [Triumvira Imunologics Inc] (herein referred to as “[Triumvira],” “we,” “us” or “our”) provides and makes available this website (the “Website”). All use of the Website is subject to the terms and conditions contained in this Terms of Use Agreement (the “Agreement”). Please read this Agreement carefully. By accessing, […] (2,001 words)
- [T Cell Therapy - Triumvira Immunologics | Engineered T Cell Therapies](/content/t-cell-therapy/index.html) (560 words)
- [designed-ankyrin-repeat-proteins-are-effective-targeting-elements-for-chimeric-antigen-receptors.html](/content/designed-ankyrin-repeat-proteins-are-effective-targeting-elements-for-chimeric-antigen-receptors.html) (76 words)
- [Company Overview - Triumvira Immunologics | Engineered T Cell Therapies](/content/about-us/company-overview/index.html) (372 words)
- [Management Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/affilation/management/index.html) (904 words)
- [How It Works - Triumvira Immunologics | Engineered T Cell Therapies](/content/our-technology/how-it-works/index.html) (637 words)
- [TAC101-CLDN18.2 - Triumvira Immunologics | Engineered T Cell Therapies](/content/programs/tac101-cldn18-2/index.html) (415 words)
- [Job Title - Triumvira Immunologics | Engineered T Cell Therapies](/content/job/job-title/index.html) (15 words)
- [Presentations & Publications - Triumvira Immunologics | Engineered T Cell Therapies](/content/scientific-presentations-publications/index.html) (143 words)
- [Scientific Advisory Council Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/affilation/scientific_advisory_council/index.html) (368 words)
- [Board of Directors Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/affilation/board_of_directors/index.html) (684 words)
- [News Articles - Triumvira Immunologics | Engineered T Cell Therapies](/content/news-articles/index.html) (83 words)
- [Job Title - Triumvira Immunologics | Engineered T Cell Therapies](/content/job/job-title-2/index.html) (8 words)
- [Job Title - Triumvira Immunologics | Engineered T Cell Therapies](/content/job/job-title-3/index.html) (15 words)
- [Our Technology - Triumvira Immunologics | Engineered T Cell Therapies](/content/our-technology/index.html) (9 words)
- [A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/a-phase-1-2-study-evaluating-the-safety-and-efficacy-of-autologous-tac-t-cells-in-subjects-with-claudin-18-2-advanced-solid-tumors-2.html): INTRODUCTION The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal to elicit a safe and durable anti-tumor response. In preclinical models, TAC-engineered T cells effectively eradicate tumor […] (156 words, Jan 31, 2025)
- [Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-presents-updated-clinical-data-at-the-2025-asco-gastrointestinal-cancers-symposium.html): AUSTIN, Texas and HAMILTON, ON and SAN DIEGO — /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, recently presented an abstract at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which […] (191 words, Jan 27, 2025)
- [Triumvira Immunologics' Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-late-breaking-abstract-selected-for-oral-presentation-at-the-39th-sitc-annual-meeting-demonstrates-preliminary-safety-and-promising-clinical-activity-of-tac01-cldn18-2-cell-th.html): HOUSTON and SAN DIEGO – Nov. 11, 2024 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that preliminary results from its Phase I/II clinical trial TACTIC-3 (NCT05862324) investigating the safety and […] (191 words, Nov 11, 2024)
- [A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/a-phase-1-2-study-evaluating-the-safety-and-efficacy-of-autologous-tac-t-cells-in-subjects-with-claudin-18-2-advanced-solid-tumors.html): INTRODUCTION The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal to elicit a safe and durable anti-tumor response. In preclinical models, TAC-engineered T cells effectively eradicate tumor […] (217 words, Nov 9, 2024)
- [Triumvira Immunologics to Present New Clinical Data from Ongoing Claudin 18.2 Phase 1 Study in Late-Breaking Oral Presentation at 39th SITC Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-new-clinical-data-from-ongoing-claudin-18-2-phase-1-study-in-late-breaking-oral-presentation-at-39th-sitc-annual-meeting.html): SAN DIEGO and AUSTIN, TX and HAMILTON, ON – Oct 30, 2024 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Dr. Ecaterina E. Dumbrava, Assistant Professor in the Department of […] (217 words, Oct 30, 2024)
- [Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-publication-demonstrating-the-safety-and-efficacy-of-tac-t-cells-targeting-claudin-18-2-in-solid-tumors.html): SAN DIEGO and AUSTIN, TX and HAMILTON, ON – Feb. 5, 2024 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the publication of a peer-reviewed article titled “Preclinical development of T cells […] (225 words, Oct 15, 2024)
- [Triumvira Immunologics Pivots to Claudin 18.2-Targeted Cell Therapy, Pauses HER2 Program - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-pivots-to-claudin-18-2-targeted-cell-therapy-pauses-her2-program.html): Article by Catherine Shaffer @ Precision Medicine Online NEW YORK – Triumvira Immunologics on Monday said it began dosing patients in a Phase I/II trial or an autologous T-cell antigen coupler (TAC) therapy, TAC101-CLDN18.2, targeting claudin 18.2 (CLDN18.2)-positive solid tumors. At the same time, in an effort to optimize finite resources, the Austin, Texas-based company […] (88 words, Feb 6, 2024)
- [Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-first-patient-dosed-in-phase-i-ii-cell-therapy-trial-of-tac101-cldn18-2-for-the-treatment-of-claudin-18-2-solid-tumors.html): SAN DIEGO and AUSTIN, TX and HAMILTON, ON – Feb. 5, 2024 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the first patient has been dosed in its TACTIC-3 trial, […] (199 words, Feb 5, 2024)
- [JPM2024: On the Ground in San Francisco - Triumvira Immunologics | Engineered T Cell Therapies](/content/jpm2024-on-the-ground-in-san-francisco/index.html): BioSpace News Editor Greg Slabodkin gives his takeaways from this year’s J.P. Morgan Healthcare Conference. After a challenging 2023, the biopharma industry appears to be turning a corner, with excitement about an improved outlook for the sector. Certain areas in particular stood out, including cell and gene therapy, artificial intelligence (AI), neuroscience and GLP1. At […] (233 words, Jan 12, 2024)
- [Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-takes-a-different-tac-with-t-cell-therapy-for-solid-tumors.html): Executive Summary The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow. You may also be interested in… Read Complete Article (39 words, Jan 10, 2024)
- [FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President - Triumvira Immunologics | Engineered T Cell Therapies](/content/fdas-car-t-probe-not-a-big-deal-for-oncology-focused-biotechs-triumvira-president.html): The CAR T sector has been under the regulatory microscope since the FDA announced in late November 2023 that it was investigating 20 reports of T cell lymphoma in patients who had previously received CAR-T therapies. However, at least one cell therapy oncology company is not concerned. At the 42nd J.P. Morgan Healthcare Conference, Triumvira […] (214 words, Jan 10, 2024)
- [Alternative Funding Strategies to Discuss at JPM - Triumvira Immunologics | Engineered T Cell Therapies](/content/alternative-funding-strategies-to-discuss-at-jpm/index.html): ABOUT THIS ROUNDTABLE The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the plunge. Given the current economic environment that is causing challenges in biopharma, how should companies be approaching funding in […] (125 words, Jan 4, 2024)
- [Triumvira Immunologics to Present Clinical Data at the 2024 ASCO Gastrointestinal Cancers Symposium - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-clinical-data-at-the-2024-asco-gastrointestinal-cancers-symposium.html): Austin, TX, Hamilton, ON and South San Francisco, CA – Dec. 19, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present two abstracts at the 2024 American […] (158 words, Dec 20, 2023)
- [What Do You See As The Most Significant Regulatory Decision Or Guidance On The Horizon For 2024 (Or Beyond)? - Triumvira Immunologics | Engineered T Cell Therapies](/content/what-do-you-see-as-the-most-significant-regulatory-decision-or-guidance-on-the-horizon-for-2024-or-beyond.html): First-in-human phase 0 imaging studies are also known as microdosing proof-of-concept studies and are designed to speed up the development of promising drugs or imaging agents by establishing very early on whether the drug or agent behaves in human subjects as was expected from preclinical studies. Distinctive features of phase 0 studies include the administration […] (270 words, Dec 15, 2023)
- [Six biopharma executives consider a tough 2023 and are hopeful for a better 2024 - Triumvira Immunologics | Engineered T Cell Therapies](/content/six-biopharma-executives-consider-a-tough-2023-and-are-hopeful-for-a-better-2024.html): BioWorld Insider Podcast One-on-one with medical innovators Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, […] (108 words, Dec 11, 2023)
- [Immune Cell Therapy May Become More Naturalistic - Triumvira Immunologics | Engineered T Cell Therapies](/content/immune-cell-therapy-may-become-more-naturalistic/index.html): By no means should cyborgs be disparaged—even if they are very small. For instance, the cellular cyborgs that serve as living drugs should be accorded the utmost respect. The U.S. Food and Drug Administration (FDA) certainly thinks so. Since 2017, the agency has approved multiple cellular cyborgs—more commonly known as chimeric antigen receptor (CAR) T-cell […] (162 words, Dec 3, 2023)
- [Finance And Funding: Anticipating Improvement, Planning For Uncertainty - Triumvira Immunologics | Engineered T Cell Therapies](/content/finance-and-funding-anticipating-improvement-planning-for-uncertainty.html): This year’s predictions on the biopharma financing and funding environment are more optimistic than they were last year, with the persistent caveat of macroeconomic uncertainty, plus unresolved litigation on policy issues such as the Inflation Reduction Act. With deal activity increasing and the promise of novel product approvals in key therapeutic areas next year, however, […] (97 words, Dec 1, 2023)
- [TAC-T Cells Persist and Remain Functional During and After Repeated Tumor Exposure In Vitor and In Vivo - Triumvira Immunologics | Engineered T Cell Therapies](/content/rd372/index.html): ABSTRACT Background T cell antigen coupler (TAC) is a chimeric receptor that redirects T cells (TAC-T) towards surface-expressed tumor antigens to create safe and durable anti-cancer immune responses. The TAC receptor activates T cells by co-opting the endogenous T cell receptor machinery via a CD3e-specific binding motif and a cytoplasmic co-receptor tail. TAC01-HER2, a first-in-class […] (371 words, Nov 4, 2023)
- [Preclinical Characterization and Modeling of Allogeneic Vγ9Vδ2 TAC T Cells for the Treatment of Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/rd400/index.html): ABSTRACT Background The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the redirection of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit safe and durable anti-tumor responses. TAC01-HER2, a first-in-class, autologous TAC T cell product targeting […] (411 words, Nov 4, 2023)
- [A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic CLDN18.2+ Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/cl738/index.html): INTRODUCTION • The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal of eliciting a safe and durable antitumor response. In preclinical models, TAC-engineered T cells effectively eradicate […] (188 words, Nov 4, 2023)
- [A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) - Triumvira Immunologics | Engineered T Cell Therapies](/content/cl654/index.html): INTRODUCTION • The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal of eliciting a safe and durable anti-tumor response. In preclinical models, TAC-engineered T cells effectively eradicate […] (231 words, Nov 4, 2023)
- [Development of GUCY2C-TAC T Cells for the Treatment of Colorectal Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/rd347/index.html): ABSTRACT Background The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the redirection of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal of eliciting safe and durable anti-tumor responses. TAC01-HER2, a first-in-class, autologous TAC T cell product targeting […] (352 words, Nov 3, 2023)
- [First Patient Dosed in Study of Cell Therapy for Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/first-patient-dosed-in-study-of-cell-therapy-for-gastric-cancer.html): From BioPharma Reporter Triumvira Immunologics, a Texas-based clinical-stage company developing T cell therapeutics to treat patients with solid tumors, has announced that the first patient has been dosed in its phase 2 trial to treat gastric cancer. Read Complete Article (44 words, Oct 30, 2023)
- [Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-new-clinical-and-preclinical-data-on-its-tac-t-cell-technology-at-sitc-2023-annual-meeting.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will participate with one oral presentation and four […] (239 words, Oct 30, 2023)
- [Phase 2 of TACTIC-2 Begins Dosing TAC01-HER2 in HER2+ Gastric/GEJ Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/phase-2-of-tactic-2-begins-dosing-tac01-her2-in-her2-gastric-gej-cancer.html): From Targeted Oncology TAC01-HER2, an autologous TAC-T cell lead asset made to target HER2 in relapsed or refractory gastric and gastroesophageal junction tumors, is being further evaluated in phase 2 of the TACTIC-2 study. The first patient with relapsed or refractory HER2-positive gastric and gastroesophageal junction (GEJ) tumors has been dosed with TAC01-HER2 in phase […] (104 words, Oct 29, 2023)
- [Triumvira Immunologics Begins Phase II Trial of T-Cell Therapy in HER2-Positive Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-begins-phase-ii-trial-of-t-cell-therapy-in-her2-positive-gastric-cancer.html): From Precision Medicine Online NEW YORK – Triumvira Immunologics said on Thursday it had begun treating patients in a Phase II trial of its autologous T-cell therapy, TAC01-HER2, in HER2-positive gastric and gastroesophageal junction cancers. The firm began the potentially registrational Phase II portion of the TACTIC-2 study, which is evaluating TAC01-HER2 as a monotherapy […] (103 words, Oct 27, 2023)
- [Triumvira Immunologics Announces First Patient Dosed in Phase II of TACTIC-2 Cell Therapy Trial for the Treatment of HER2+ Gastric and GEJ Cancers - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-first-patient-dosed-in-phase-ii-of-tactic-2-cell-therapy-trial-for-the-treatment-of-her2-gastric-and-gej-cancers.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the first patient has been dosed in Phase II […] (268 words, Oct 26, 2023)
- [Triumvira Immunologics to Present Clinical Data from TACTIC-2 Trial Investigating TAC01-HER2 at ESMO 2023 Congress and AACR-NCI-EORTC International Conference - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-clinical-data-from-tactic-2-trial-investigating-tac01-her2-at-esmo-2023-congress-and-aacr-nci-eortc-international-conference.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present clinical data from its ongoing Phase […] (146 words, Oct 2, 2023)
- [The Top 25 Healthcare Technology Leaders of Austin for 2023 - Triumvira Immunologics | Engineered T Cell Therapies](/content/the-top-25-healthcare-technology-leaders-of-austin-for-2023.html): From The Healthcare Technology Report The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Austin for 2023. Undoubtedly, Austin stands as a bastion of health and well-being. Its extensive network of hiking, biking, and running trails, complemented by a state-of-the-art velodrome catering to cycling enthusiasts, reflects the city’s unwavering […] (181 words, Sep 18, 2023)
- [Decoding Cell Therapy Variants with Dr Andy Bader - Triumvira Immunologics | Engineered T Cell Therapies](/content/decoding-cell-therapy-variants-with-dr-andy-bader/index.html): From Drug Target Review The field of cell therapy has emerged as a beacon of hope, promising transformative treatments for various diseases. Diving into the intricacies of this domain, this exclusive interview explores the distinctions between two key approaches – autologous and allogeneic cell therapies. We look at the nuances of cell sourcing, preclinical challenges, […] (87 words, Sep 1, 2023)
- [Conquering New Frontiers in Cell Therapy, Paul Lammers, CEO, Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies](/content/conquering-new-frontiers-in-cell-therapy-paul-lammers-ceo-triumvira-immunologics.html): From BioTech 2050 Podcast Paul Lammers, M.D., is the CEO of Triumvira Immunologics, a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer. A Dutch-trained biologist and physician, Paul talks about starting his career in […] (152 words, Aug 16, 2023)
- [Advancements in Cell Therapy for Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/advancements-in-cell-therapy-for-solid-tumors/index.html): In the first of 3 videos, Paul Lammers, MD, MSc, chief executive officer of Triumvira, discusses the company’s unique T antigen coupler (TAC) T-cell technology. Daniel Olson, MD, Assistant Professor of Medicine, the University of Chicago Medicine, presented an abstract about the ongoing phase 1/2 study evaluating the safety and efficacy of TAC01 in HER2-expressing […] (94 words, Aug 11, 2023)
- [Biotech M&A Rebound Bodes Well for Venture Investors - Triumvira Immunologics | Engineered T Cell Therapies](/content/biotech-ma-rebound-bodes-well-for-venture-investors.html): Regulatory scrutiny of acquisitions could slow momentum Biotechnology mergers and acquisitions are rebounding, a promising development for venture capitalists at a time when few startups are going public. Top drugmakers could soon forfeit billions in revenue as medications lose patent protection. Meanwhile, valuations of smaller biotech companies have retreated from pandemic-era highs, leading to more […] (99 words, Aug 10, 2023)
- [Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-strengthens-its-leadership-team-with-three-accomplished-life-sciences-executives.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., July 20, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the strengthening of its leadership team with the appointments of […] (171 words, Jul 20, 2023)
- [Claudin-18.2 attracts the cancer crowd - Triumvira Immunologics | Engineered T Cell Therapies](/content/claudin-18-2-attracts-the-cancer-crowd/index.html): Astellas’s claudin-18.2-targeted antibody zolbetuximab provides a benefit in hard-to-treat metastatic gastric cancer, and leads a multi-modality herd of contenders. Gastric cancer is a beast. Despite being the fourth most fatal cancer worldwide — killing nearly 770,000 people per year — drug developers have made little headway against it in decades. For most patients with metastatic […] (111 words, Jul 17, 2023)
- [Triumvira Immunologics to Showcase Clinical Findings from TACTIC-2 Clinical Trial Assessing TAC01-HER2 at 2023 ESMO World Congress on Gastrointestinal Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-showcase-clinical-findings-from-tactic-2-clinical-trial-assessing-tac01-her2-at-2023-esmo-world-congress-on-gastrointestinal-cancer.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., June 28, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will be presenting clinical data on its lead […] (271 words, Jun 28, 2023)
- [Triumvira shares upcoming plans for accelerated approval with cell therapies - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-shares-upcoming-plans-for-accelerated-approval-with-cell-therapies.html): US-based Triumvira Immunologics will aim for accelerated approval for its TAC01-HER2 by the US Food and Drug Administration (FDA) in gastric and oesophageal cancers, chief medical officer Dr. Deyaa Adib told Clinical Trials Arena. Adib noted: “It’s an area of significant unmet medical needs, where the standard of care has not changed over the last […] (144 words, Jun 15, 2023)
- [DDW Events: AACR 2023 Episode 2 with Andreas Bader, Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies](/content/ddw-events-aacr-2023-episode-2-with-andreas-bader-triumvira-immunologics.html): At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. Listen to the Podcast In this latest episode, Thomas speaks with Andreas Bader, Chief Scientific Officer at Triumvira Immunologics. Read Complete Article (82 words, Jun 14, 2023)
- [Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/dr-schlechter-on-tac01-her2-therapy-in-her2-solid-tumors.html): Benjamin L. Schlechter, MD, senior physician, Dana-Farber Cancer Institute, instructor, medicine, Harvard Medical School, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors. Watch the Video The ongoing, phase 1/2 TACTIC-2 trial (NCT04727151) is evaluating the efficacy and safety of autologous TAC01-HER2 T-cell therapy in patients with HER2-positive breast, colorectal, gall […] (163 words, Jun 9, 2023)
- [Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-highlights-positive-phase-1-clinical-data-on-tac01-her2-in-solid-tumors-at-asco-2023-annual-meeting.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., May 31, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that positive data from its Phase I/II trial investigating the safety […] (259 words, May 31, 2023)
- [A Different Approach, A New Cancer Drug... Dr. Paul Lammers, CEO Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies](/content/a-different-approach-a-new-cancer-drug-dr-paul-lammers-ceo-triumvira-immunologics.html): Cancer treatments that work with the immune system are making great strides, with Keytruda from Merck being perhaps the best known. Still, there is much work to be done – both in developing unprecedented new treatments, as well as treatments that might combine with our existing treatments to make them even more effective. Triumvera (try-um-VEERA) […] (112 words, May 17, 2023)
- [Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-clinical-data-from-phase-i-ii-trial-tactic-2-investigating-tac01-her2-at-the-2023-asco-annual-meeting.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., May 16, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the Company will be presenting clinical data on its […] (249 words, May 16, 2023)
- [Joy and Boldness in Drug Development – with Paul Lammers - Triumvira Immunologics | Engineered T Cell Therapies](/content/joy-and-boldness-in-drug-development-with-paul-lammers.html): Join us in this episode as we talk with Paul Lammers, CEO of Triumvira Immunologics, a clinical-stage biopharmaceutical company focusing on developing T cell therapies for cancer treatment. Born in the Netherlands and now an American citizen, Lammers’ early life shaped his views on being bold and making connections with people a priority. He shares […] (212 words, Apr 24, 2023)
- [Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-presents-promising-data-on-tac-t-cells-for-the-treatment-of-her2-overexpressing-solid-tumors-at-the-2023-aacr-annual-meeting.html): AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., April 18, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics, today announced the details of the Company’s presentation at the 2023 AACR Annual Meeting on its lead asset, TAC01-HER2, for the treatment of human epidermal growth […] (147 words, Apr 18, 2023)
- [Engineering Better Cell Therapies for Cancers - Triumvira Immunologics | Engineered T Cell Therapies](/content/engineering-better-cell-therapies-for-cancers/index.html): Cell therapies are revolutionizing the way cancers are treated, but existing cell therapies have their limits. They have been more successful at treating hematologic tumors than solid tumors, and they can sometimes cause serious side effects, such as the destruction of antibodies or what’s known as cytokine storms in which the immune system gets over-revved […] (176 words, Mar 29, 2023)
- [First in Human Episode #25 featuring Dr. Paul Lammers - Triumvira Immunologics | Engineered T Cell Therapies](/content/first-in-human-episode-25-featuring-dr-paul-lammers.html): For episode 25, we sit down with Dr. Paul Lammers, CEO of Triumvira Immunologics. Stay tuned to learn why having multiple programs in clinical trials can provide a safety net should one program fail and how it adds additional value for investors. First In Human is a biotech-focused podcast that interviews industry leaders and investors […] (100 words, Mar 28, 2023)
- [Triumvira Immunologics - T-Cell Therapeutics - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-t-cell-therapeutics/index.html): In this Health Professional Radio interview – Learn how Triumvira Immunologics is developing novel T-Cell therapies to treat cancer patients. Discover how their autologous and allogeneic targeted therapeutics co-opt the natural biology of T cells. Find out more from CEO Dr. Paul Lammers. Watch Interview (80 words, Mar 22, 2023)
- [On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions - Triumvira Immunologics | Engineered T Cell Therapies](/content/on-the-backside-of-the-hype-cycle-cancer-cell-therapy-companies-grappling-with-lofty-expectations-and-challenging-market-conditions.html): Join us for the third session in Lumanity’s New Cancer Progress Webinar series, “On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling With Lofty Expectations and Challenging Market Conditions,” on April 26th at 1:00pm ET moderated by Joel Sandler, Ph.D.. Hear from Mike DeRidder, Ajla Hrle, Michael Kalos, and Paul Lammers as […] (82 words, Mar 21, 2023)
- [JPM Highlights: What’s Next in ImmunoOncology - Triumvira Immunologics | Engineered T Cell Therapies](/content/jpm-highlights-whats-next-in-immunooncology/index.html): In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s mission is to […] (315 words, Mar 20, 2023)
- [SVB fall casts shadow on early-stage U.S. biotech - Triumvira Immunologics | Engineered T Cell Therapies](/content/svb-fall-casts-shadow-on-early-stage-u-s-biotech/index.html): The collapse of Silicon Valley Bank (SIVB.O) will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape unscathed. About 50% of U.S. biotech companies, developing drugs for everything from cancer to heart disease and rare conditions, banked with Silicon Valley Bank (SVB), including […] (83 words, Mar 13, 2023)
- [T Cell Antigen Coupler Platform Generating Patient-Derived Cell Therapies to Target Solid Tumors with Dr. Paul Lammers Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies](/content/t-cell-antigen-coupler-platform-generating-patient-derived-cell-therapies-to-target-solid-tumors-with-dr-paul-lammers-triumvira-immunologics.html): Dr. Paul Lammers, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells. At the forefront of the next generation of immune-oncology, Triumvira uses the Cocoon Platform made by Lonza to […] (211 words, Mar 13, 2023)
- [Inside Insight: Nature knows best for Triumvira's cell therapy - Triumvira Immunologics | Engineered T Cell Therapies](/content/inside-insight-nature-knows-best-for-triumviras-cell-therapy.html): While many cell therapy developers are embracing every change they can engineer to optimize their CAR constructs, the messaging from Triumvira Immunologics is to keep it simple. By combining the best features of CAR-T and TCR therapies, it’s hoping to create a cell therapy to competitively take on both liquid and solid tumors. Avoiding drawbacks […] (154 words, Mar 7, 2023)
- [Biotech CFOs sharpen financing tactics for lean times - Triumvira Immunologics | Engineered T Cell Therapies](/content/biotech-cfos-sharpen-financing-tactics-for-lean-times-2.html): In today’s challenging market, some biotech companies are going the extra mile to keep their existing investors, reopening earlier rounds and moving to rolling closings. CFOs of early-stage biotechnology firms get a lot of practice in the art of raising money. No matter the market cycle, they must find capital to fund costly research that […] (167 words, Jan 17, 2023)
- [Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-establishes-collaboration-with-merck-to-evaluate-tac01-her2-cell-therapy-in-combination-with-keytruda-pembrolizumab-in-patients-with-her2-positive-solid-tumors.html): Clinical activity observed in third dosing cohort and sustained clinical benefit in second cohort AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced […] (185 words, Jan 6, 2023)
- [Other news to note for Jan. 5, 2023 - Triumvira Immunologics | Engineered T Cell Therapies](/content/other-news-to-note-for-jan-5-2023/index.html): After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelyrin, Adcendo, Algernon, Bayer, Boehringer Ingelheim, Caris, Celmatix, Duality, Esperovax, Evotec, Ginkgo, Lumen, Merck & Co., Nouscom, Orbit, Orna, Paratek, Phoremost, Sanegene, Simnova Xianbo, Triumvira, Variational Ai, Xencor, […] (78 words, Jan 5, 2023)
- [Tales From the 2022 Biotech VC Fundraising Trail - Triumvira Immunologics | Engineered T Cell Therapies](/content/tales-from-the-2022-biotech-vc-fundraising-trail/index.html): After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted Biotechnology entrepreneurs recalibrated in 2022 as their financing options narrowed, a reversal from years in which life-sciences startups were flush with capital. With just two weeks left in the year, U.S. biotechs had raked in $29.7 billion for 2022, compared with the […] (68 words, Dec 22, 2022)
- [Triumvira Immunologics Announces Updated Data from Ongoing TACTIC‑2 Trial of TAC01-HER2 in Patients with HER2 Positive Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-updated-data-from-ongoing-tactic-e2-80-912-trial-of-tac01-her2-in-patients-with-her2-positive-solid-tumors.html): Clinical activity observed in third dosing cohort and sustained clinical benefit in second cohort AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced updated […] (245 words, Nov 11, 2022)
- [A Phase I/II Trial Investigation Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refactory Solid Tumors (Tactic-2) - Triumvira Immunologics | Engineered T Cell Therapies](/content/a-phase-i-ii-trial-investigation-safety-and-efficacy-of-autologous-tac-t-cells-targeting-her2-in-relapsed-or-refactory-solid-tumors-tactic-2.html): INTRODUCTION • The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal to elicit a safe and durable anti-tumor response. In preclinical models of cancer, TAC-engineered T cells […] (167 words, Nov 11, 2022)
- [Evidence for Durable Anti-Tumor Responses by TAC-T Cells in Preclinical Models of Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/evidence-for-durable-anti-tumor-responses-by-tac-t-cells-in-preclinical-models-of-solid-tumors.html): ABSTRACT Background T cell antigen coupler (TAC) is a chimeric receptor that redirects T cells (TAC-T) towards surface-expressed tumor antigens to create safe and durable anti-cancer immune responses. The TAC activates T cells by co-opting the endogenous T cell receptor machinery via a CD3ε-specific binding motif and a cytoplasmic co-receptor tail. TAC01-HER2, a first-in-class TAC-T […] (407 words, Nov 10, 2022)
- [Development of GUCY2C-TAC T Cells for the Treatment of Colorectal Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/development-of-gucy2c-tac-t-cells-for-the-treatment-of-colorectal-cancer.html): ABSTRACT Background The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the redirection of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit safe and durable anti-tumor responses. TAC01-HER2, a first-in-class TAC T product targeting HER2 (ERBB2), […] (375 words, Nov 10, 2022)
- [Preclinical Studies of TAC01-CLDN18.2, an Autologous Claudin 18.2-Directed TACT T Cell Therapy, for the Treatment of Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/preclinical-studies-of-tac01-cldn18-2-an-autologous-claudin-18-2-directed-tact-t-cell-therapy-for-the-treatment-of-gastric-cancer.html): ABSTRACT Background The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the redirection of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit safe and durable anti-tumor responses. TAC01-HER2, a first-in-class TAC T product targeting HER2 (ERBB2), […] (352 words, Nov 10, 2022)
- [Triumvira Immunologics Demonstrates Strength of Preclinical Research Pipeline for Gastric and Colorectal Cancers in Three Posters at SITC 2022 - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-demonstrates-strength-of-preclinical-research-pipeline-for-gastric-and-colorectal-cancers-in-three-posters-at-sitc-2022.html): AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data […] (186 words, Nov 10, 2022)
- [Benjamin L. Schlechter, MD, on Addressing Unmet Needs in HER2 Positive Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/benjamin-l-schlechter-md-on-addressing-unmet-needs-in-her2-positive-solid-tumors.html): “There’s sort of 2 big groups of HER2 solid tumors: there’s the breast cancer population, and there’s everybody else. The reality in breast cancers is there’s a myriad of effective treatments: cytotoxics, antibody-drug conjugates, combinations, monoclonal antibodies, and targeted therapies. And those have had much less benefit in other HER2-positive malignancies… HER2 therapy has not […] (192 words, Oct 31, 2022)
- [Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-clinical-and-preclinical-updates-at-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting.html): AUSTIN, Texas, and HAMILTON, Ontario – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) […] (184 words, Oct 27, 2022)
- [Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-appoints-life-sciences-industry-leader-robert-williamson-as-president-and-chief-business-officer.html): AUSTIN, Texas, and HAMILTON, Ontario – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced the appointment of Robert Williamson as President and Chief Business Officer. Mr. Williamson will lead business development and strategy for Triumvira, […] (218 words, Oct 25, 2022)
- [Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco.html): AUSTIN, Texas, and HAMILTON, Ontario – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to manufacture its own cell […] (173 words, Oct 19, 2022)
- [Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022 - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-participate-in-four-upcoming-healthcare-investor-conferences-in-october-and-november-2022.html): AUSTIN, Texas, and HAMILTON, Ontario – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Senior Management will participate in four upcoming healthcare investor conferences. Oppenheimer Private Company Showcase: The Next Wave: presentation at […] (130 words, Oct 12, 2022)
- [Triumvira Immunologics Presents Initial HER2-Positive Solid Tumor Clinical Data at ESMO - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-presents-initial-her2-positive-solid-tumor-clinical-data-at-esmo.html): Early signals of clinical activity observed in second dosing cohort with one partial response TAC01-HER2 was safe and well-tolerated in the first two dosing cohorts of TACTIC-2 Phase 1/2 clinical trial AUSTIN, Texas, and HAMILTON, Ontario, Sep. 12, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt […] (339 words, Sep 12, 2022)
- [A Phase I/II Trial Investigating Safety and Efficacy of Autologous T Cell Antigen-Coupler (TAC) T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) (ESMO Report) - Triumvira Immunologics | Engineered T Cell Therapies](/content/a-phase-i-ii-trial-investigating-safety-and-efficacy-of-autologous-t-cell-antigen-coupler-tac-t-cells-targeting-her2-in-relapsed-or-refractory-solid-tumors-tactic-2-august-2022.html): Introduction: The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re‑direction of T cells to tumor cells and activates T cells by co‑opting the endogenous T cell receptor complex, with the goal to elicit a safe and durable anti‑tumor response. In preclinical models of cancer, TAC‑engineered T cells effectively […] (152 words, Sep 10, 2022)
- [Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-interim-clinical-data-from-ongoing-phase-1-2-trial-with-t-cell-therapy-tac01-her2-at-european-society-for-medical-oncology-2022-congress.html): AUSTIN, Texas, and HAMILTON, Ontario, Sep. 6, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in […] (183 words, Sep 6, 2022)
- [A Phase I/II Trial Investigating Safety and Efficacy of Autologous T Cell Antigen-Coupler (TAC) T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) - Triumvira Immunologics | Engineered T Cell Therapies](/content/a-phase-i-ii-trial-investigating-safety-and-efficacy-of-autologous-t-cell-antigen-coupler-tac-t-cells-targeting-her2-in-relapsed-or-refractory-solid-tumors-tactic-2.html): Background: Despite recent therapeutic advances for patients with breast, colorectal and gastroesophageal cancers with HER2 overexpression, there is still a significant unmet medical need for better treatment options for HER2-positive solid tumors, especially those with low or intermediate HER2 expression (1+ and 2+ by immunohistochemistry (IHC)). The T Cell Antigen-Coupler (TAC) technology is a novel […] (87 words, Aug 12, 2022)
- [CAR T cells headline HER2 cell therapy pipeline - Triumvira Immunologics | Engineered T Cell Therapies](/content/car-t-cells-headline-her2-cell-therapy-pipeline/index.html): CAR T cells are the most popular strategy to hit the solid tumor-selective target, but companies are using at least five other methods By Danielle Golovin / BioCentury Staff Writer June 23, 2022 CAR T cells are the most popular strategy to hit the solid tumor-selective target, but companies are using at least five other […] (552 words, Jun 23, 2022)
- [L7 Informatics and Triumvira Immunologics Announce Agreement to Digitalize Manufacturing of Next-Generation Cell Therapies - Triumvira Immunologics | Engineered T Cell Therapies](/content/l7-informatics-and-triumvira-immunologics-announce-agreement-to-digitalize-manufacturing-of-next-generation-cell-therapies.html): Clinical-stage biotech to implement a unified platform with a single data fabric versus point solutions AUSTIN, Texas, and HAMILTON, Ontario, May 31, 2022 – L7 Informatics, the leader in DATA+INTELLIGENCE for the scientific enterprise, and Triumvira Immunologics (“Triumvira”) today announced an agreement to implement L7|ESP at Triumvira to enhance the digitalization of its manufacturing of next-generation cell […] (134 words, May 31, 2022)
- [Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022 - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-two-posters-covering-ongoing-phase-1-2-solid-tumor-trial-and-new-preclinical-gastric-cancer-data-at-aacr-annual-meeting-2022.html): Triumvira to initiate enrollment of second cohort in ongoing Phase 1/2 trial of TAC01-HER2 following data safety monitoring committee’s successful review of safety data from first cohort AUSTIN, Texas, and HAMILTON, Ontario, April 10, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T […] (151 words, Apr 10, 2022)
- [Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-completes-extension-of-series-a-financing-for-total-round-of-approximately-100-million.html): AUSTIN, Texas, and HAMILTON, Ontario, March 17, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. […] (146 words, Mar 17, 2022)
- [Triumvira Immunologics Establishes Scientific Advisory Board - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-establishes-scientific-advisory-board.html): Novel CLDN18.2-TAC T cell candidate effectively eradicated Claudin 18.2-expressing gastric tumor cells in vitro and in vivo AUSTIN, Texas, and HAMILTON, Ontario, November 13, 2021 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that […] (103 words, Feb 11, 2022)
- [Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-announces-data-from-gastric-cancer-preclinical-study-to-be-presented-at-sitc-annual-meeting.html): Novel CLDN18.2-TAC T cell candidate effectively eradicated Claudin 18.2-expressing gastric tumor cells in vitro and in vivo AUSTIN, Texas, and HAMILTON, Ontario, November 13, 2021 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients […] (145 words, Nov 13, 2021)
- [Development of Claudin 18.2-TAC T Cells for the Treatment of Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies](/content/development-of-claudin-18-2-tac-t-cells-for-the-treatment-of-gastric-cancer.html): Christopher W. Helsen, Tania Benatar, Thanyashanthi Nitya-Nootan, Heather McGregor, Philbert Ip, Prabha Lal, Stacey Xu, Laura Shaver, Suzy Prosser, Sadhak Sengupta, Andreas G. Bader. Triumvira Immunologics, 9433 Bee Caves Rd Building 1, Suite 240, Austin, TX 78733, USA (Headquarters), 270 Longwood Road South, Hamilton, Ontario L8P 0A6, Canada (Research Division) Abstract The T cell antigen […] (133 words, Nov 13, 2021)
- [Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D., as Chief Medical Officer - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-appoints-oncology-industry-veteran-deyaa-adib-m-d-as-chief-medical-officer.html): AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it has appointed Deyaa Adib, M.D., to serve as the company’s Chief Medical Officer, effective immediately. Dr. Adib […] (268 words, Oct 28, 2021)
- [Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-doses-first-patient-with-novel-t-cell-therapy-in-tactic-2-clinical-trial.html): TACTIC-2 marks first in-human use of TAC-T cell therapy Phase 1/2 clinical trial will evaluate TAC01-HER2, Triumvira’s lead candidate, in patients with HER2-overexpressing solid tumors First patient dosed at MD Anderson Cancer Center in Houston, Texas AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”) today announced that the first patient has been dosed as part […] (147 words, Sep 20, 2021)
- [Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-appoints-teresa-mcroberts-as-chief-financial-officer-and-announces-senior-level-promotions-2.html): AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin […] (193 words, Apr 26, 2021)
- [Top Life Sciences Startups to Watch in 2021 - Triumvira Immunologics | Engineered T Cell Therapies](/content/top-life-sciences-startups-to-watch-in-2021-2/index.html) (148 words, Jan 7, 2021)
- [Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies](/content/bayer-and-northpond-ventures-lead-usd-55-million-series-a-financing-round-for-triumvira-immunologics-2.html): LEVERKUSEN, Germany & AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine […] (219 words, Aug 28, 2020)
- [Triumvira Announces Grant of T Cell Antigen Coupler (TAC) Technology Patent by U.S. Patent and Trademark Office - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-announces-grant-of-t-cell-antigen-coupler-tac-technology-patent-by-u-s-patent-and-trademark-office-2.html) (138 words, May 6, 2020)
- [Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-and-lonza-announce-collaboration-to-develop-innovative-point-of-care-manufacturing-for-tac-t-cell-therapeutic-targeting-solid-tumors.html): AUSTIN, Texas & HAMILTON, Ontario & BASEL, Switzerland–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, and Lonza, a leading cell & gene therapy manufacturer, announced today that the companies have an agreement in place. This collaboration, aimed at the development of Triumvira’s TAC01-HER2 […] (164 words, Mar 24, 2020)
- [Triumvira Immunologics Announces Fast Track Designation for Its First TAC T-Cell Therapeutic Product Candidate: TAC01-CD19 - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-fast-track-designation-for-its-first-tac-t-cell-therapeutic-product-candidate-tac01-cd19.html): AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its novel T-cell therapy product TAC01-CD19 in patients with relapsed or refractory Diffuse Large B-Cell […] (191 words, Nov 7, 2019)
- [Triumvira Immunologics Announces Clearance of IND and CTA by U.S. FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19 - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-clearance-of-ind-and-cta-by-u-s-fda-and-health-canada-for-its-first-tac-t-cell-therapeutic-product-candidate-tac01-cd19.html): Clinical trials of TAC01-CD19 expected to begin in third quarter 2019 AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)– Triumvira Immunologics, Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that both the U.S. Food & Drug Administration (FDA) and Health Canada have cleared […] (519 words, Jun 18, 2019)
- [Triumvira Announces Addition of Veteran VP of Regulatory Affairs, Presentations at CellCAN and TRI-CON Conferences, and Attendance at Bio-Europe Partnering - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-announces-addition-of-veteran-vp-of-regulatory-affairs-presentations-at-cellcan-and-tri-con-conferences-and-attendance-at-bio-europe-partnering.html): AUSTIN, TX, and HAMILTON, ON, March 13, 2019 – Triumvira Immunologics, Inc., (Triumvira) a privately held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the appointment of Cynthia Molina as Vice President of Regulatory Affairs. In this position, Cynthia will be responsible for global regulatory strategic development, oversight of […] (610 words, Mar 13, 2019)
- [Q&A with Dr. Paul Lammers, President and CEO of Triumvira Immunologics developing their T-Cell Antigen Coupler Technology to activate T-Cells in the treatment of Advanced Hematological Cancers and Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies](/content/qa-with-dr-paul-lammers-president-and-ceo-of-triumvira-immunologics-developing-their-t-cell-antigen-coupler-technology-to-activate-t-cells-in-the-treatment-of-advanced-hematological-cancers-and-sol.html): Dr. Paul Lammers President & Chief Executive Officer Triumvira Immunologics www.triumvira.com Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – March 4, 2019 CEOCFO: Dr. Lammers, you have been president and CEO for a little over a year now. What attracted you to Triumvira Immunologics, Inc? Dr. Lammers: When I started to look […] (591 words, Mar 4, 2019)
- [Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement - Triumvira Immunologics | Engineered T Cell Therapies](/content/knight-therapeutics-and-triumvira-immunologics-triumphantly-announce-secured-bridge-loan-license-agreement.html): MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. (“Triumvira”). The US$5 […] (181 words, Feb 20, 2019)
- [Triumvira Immunologics to Present at CAR-T Congress EU in London, UK - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-at-car-t-congress-eu-in-london-uk.html): AUSTIN, Texas, and HAMILTON, Ontario, January 29, 2019 – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that Dr. Paul Lammers, President & CEO, will both present and moderate a round table discussion at the CAR-T Congress EU, to be held in London […] (448 words, Jan 29, 2019)
- [Triumvira Announces Build Out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-announces-build-out-of-senior-management-team-with-addition-of-industry-experienced-professionals-in-rd-and-business-development.html): AUSTIN, Texas & HAMILTON, Ontario & TORONTO – AUSTIN, Texas, and HAMILTON, Ontario, January 23, 2019 – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointments of Andreas Bader as Senior Vice President of Research & Development, and Joshua Carle as Vice […] (541 words, Jan 24, 2019)
- [Triumvira Immunologics to Present at Biotech Showcase™ 2019 in San Francisco - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-at-biotech-showcase-2019-in-san-francisco.html): AUSTIN, Texas & HAMILTON, Ontario & TORONTO – Triumvira Immunologics Inc., announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week for healthcare investors at the Hilton San Francisco Union Square. Paul Lammers, MD, MSc, President and Chief Executive Officer, will present at Biotech Showcase™ as […] (516 words, Jan 4, 2019)
- [Triumvira Immunologics Demonstrates Prolonged TAC-T Cell Persistence and Efficacy in Preclinical Models - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-demonstrates-prolonged-tac-t-cell-persistence-and-efficacy-in-preclinical-models.html): AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), announced the presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, held December 1-4, 2018, in San Diego, CA. The data show that TAC-engineered T cells provide long-lasting tumor rejection in mouse models of BCMA-positive and […] (548 words, Dec 4, 2018)
- [Triumvira Immunologics Announces Presentation of Key Preclinical Data on TAC Technology at American Society of Hematology - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-presentation-of-key-preclinical-data-on-tac-technology-at-american-society-of-hematology.html): AUSTIN, Texas & HAMILTON, Ontario & TORONTO—Triumvira Immunologics Inc. (Triumvira), announced the upcoming presentation of key preclinical data at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, December 1-4, 2018, in San Diego, CA. The data will be presented during a poster presentation on Sunday, December 2, and a podium presentation on […] (382 words, Nov 29, 2018)
- [CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates - Triumvira Immunologics | Engineered T Cell Therapies](/content/ccab-and-triumvira-immunologics-announce-triumviras-license-agreement-with-university-of-toronto-for-the-discovery-of-antibody-drug-development-candidates.html): AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)–The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc. (Triumvira), announced today a new licensing agreement between the University of Toronto (U of T) and Triumvira. The agreement provides Triumvira with an exclusive license for antibodies discovered at the U of T on […] (512 words, Sep 10, 2018)
- [Triumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-presents-data-on-t-cell-antigen-coupler-tac-technology-at-the-6th-annual-immuno-oncology-summit.html): TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors AUSTIN, TX, and HAMILTON, ON, August 30, 2018 – Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, will present data today on its novel T cell therapy technology, […] (512 words, Aug 30, 2018)
- [The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity - Triumvira Immunologics | Engineered T Cell Therapies](/content/the-chimeric-tac-receptor-co-opts-the-t-cell-receptor-yielding-robust-anti-tumor-activity-without-toxicity-2.html): Helsen CW, Hammill JA, Lau VWC, Mwawasi KA, Afsahi A, Bezverbnaya K, Newhook L, Hayes DL, Aarts C, Bojovic B, Denisova GF, Kwiecien JM, Brain I, Derocher H, Milne K, Nelson BH, Bramson JL. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nature Communications. 2018;9:3049. doi:10.1038/s41467-018-05395-y. PMC. Web. 21 […] (71 words, Aug 3, 2018)
- [Nature Communications Publishes Studies Comparing Triumvira’s T Cell Antigen Coupler (TAC) Technology with CAR T Cell Therapy - Triumvira Immunologics | Engineered T Cell Therapies](/content/nature-communications-publishes-studies-comparing-triumviras-t-cell-antigen-coupler-tac-technology-with-car-t-cell-therapy.html): Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy AUSTIN, TX, and HAMILTON, ON, August 3, 2018 – Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies today announced the publication of a peer-reviewed article in today’s edition of […] (489 words, Aug 3, 2018)
- [Triumvira Immunologics Appoints Scott Smith to Board of Directors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-appoints-scott-smith-of-celgene-to-board-of-directors.html): Innovative immuno-therapy company welcomes former President and COO of Celgene AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Scott Smith to the Board of Directors. “We are thrilled to welcome Scott to the Triumvira Board […] (133 words, Jun 25, 2018)
- [Triumvira Hires Donna Rill as Chief Technology Officer - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-hires-donna-rill-as-chief-technology-officer.html): Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Donna Rill as Chief Technology Officer. As CTO, Rill will use her extensive technology development and manufacturing experience to […] (131 words, Jun 11, 2018)
- [Triumvira Immunologics to Participate in Two Upcoming Conferences - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-participate-in-two-upcoming-conferences.html): Sachs Immuno-Oncology BD&L and Investment Forum and 2018 BIO International Convention AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present a company overview at the 4th Annual Immuno-Oncology Business Development & […] (467 words, May 31, 2018)
- [4th Annual Immuno-Oncology BD&L and Investment Forum - Triumvira Immunologics | Engineered T Cell Therapies](/content/4th-annual-immuno-oncology-bdl-and-investment-forum.html): Dr. Jonathan Bramson to be presenting at 3:20 p.m. CT on June 1. At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical […] (106 words, May 30, 2018)
- [2018 BIO International Convention - Triumvira Immunologics | Engineered T Cell Therapies](/content/2018-bio-international-convention/index.html): Triumvira President and Chief Executive Officer, Dr. Paul Lammers available for private meetings June 4-5 At BIO International, Triumvira Immunologics President and Chief Executive Officer, Dr. Paul Lammers will be available for private meetings during the day on June 4-5 to discuss potential collaboration and licensing opportunities for the Company’s novel immuno-oncology platform T Cell-Antigen […] (90 words, May 30, 2018)
- [Triumvira Expands Management Team with Chief Medical Officer and VP, Finance - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-expands-management-team-with-chief-medical-officer-and-vp-finance.html): Innovative immuno-therapy company welcomes proven leaders in pharma and therapeutics AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today formally announced the appointments of Sabine Chlosta, MD, PhD, as Chief Medical Officer, and Jon Irvin as Vice President, Finance. […] (568 words, May 17, 2018)
- [Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-announces-strategic-relationship-for-gmp-manufacturing-with-centre-for-commercialisation-of-cancer-immunotherapy.html): AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the […] (163 words, May 2, 2018)
- [International Society for Cellular Therapy 2018 - Triumvira Immunologics | Engineered T Cell Therapies](/content/international-society-for-cellular-therapy-2018/index.html): Triumvira will be presenting at ISCT 2018 – May 2-5, 2018 at the Palais des Congrès de Montréal in Montréal, QC, Canada ISCT is the premier cell therapy translation society focused on pre-clinical, clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice […] (125 words, Apr 30, 2018)
- [Triumvira Immunologics to Present at Two Upcoming Conferences: - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-to-present-at-two-upcoming-conferences-international-society-for-cellular-therapy-and-bloom-burton-co-healthcare-investor-conference.html): International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present an abstract at the International Society for Cellular Therapy […] (137 words, Apr 30, 2018)
- [Bloom Burton & Co. Healthcare Investor Conference - Triumvira Immunologics | Engineered T Cell Therapies](/content/bloom-burton-co-healthcare-investor-conference/index.html): Triumvira will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on May 2 and 3, 2018 at the Sheraton Centre Toronto Hotel in Toronto, ON., Canada This year, BBHIC will host approximately 60 of Canada’s premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. […] (98 words, Apr 12, 2018)
- [Triumvira Immunologics Appoints Cynthia Collins to Board of Directors - Triumvira Immunologics | Engineered T Cell Therapies](/content/triumvira-immunologics-appoints-cynthia-collins-to-board-of-directors.html): Innovative immuno-therapy company welcomes a recognized leader in life sciences and therapeutics AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, a privately-held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Cynthia (Cindy) Collins to the Board of Directors. “We are very pleased that Cindy has joined Triumvira,” […] (112 words, Apr 5, 2018)
- [LaVoieHealthScience Expands Senior Leadership Team, Adds Two New Immuno-Oncology Clients to Roster - Triumvira Immunologics | Engineered T Cell Therapies](/content/lavoiehealthscience-expands-senior-leadership-team-adds-two-new-immuno-oncology-clients-to-roster.html): Douglas Russell joins LHS as Senior Vice President & General Manager BOSTON–(BUSINESS WIRE)–LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the continued growth of its strategic communications team with the hiring of Douglas Russell, who is joining LHS as Senior Vice President and General Manager, […] (187 words, Mar 1, 2018)
- [Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer - Triumvira Immunologics | Engineered T Cell Therapies](/content/paul-lammers-m-d-m-sc-joins-triumvira-as-president-and-chief-executive-officer.html): Experienced biotech executive takes helm of promising T-Cell Therapy company as it moves several programs toward clinical testing HAMILTON, Ontario & AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics Canada Inc. and Triumvira Immunologics USA Inc. today announced the appointment of Paul Lammers, M.D., M.Sc., as President and Chief Executive Officer. Dr. Lammers brings more than 27 years of […] (145 words, Jan 4, 2018)
- [Hamilton researchers: White blood cells could be made to hunt cancer cells - Triumvira Immunologics | Engineered T Cell Therapies](/content/hamilton-researchers-white-blood-cells-could-be-made-to-hunt-cancer-cells.html): Hamilton researchers will attempt to take the blinders off of white blood cells so the immune system can spot cancer and fight it. The intention is for their discovery to be turned into new cancer drugs developed by biotechnology company Triumvira Immunologics opening up in McMaster Innovation Park. The partnership is getting $2.3 million from […] (96 words, Dec 1, 2017)
- [Tumor-targeting domains for chimeric antigen receptor T cells - Triumvira Immunologics | Engineered T Cell Therapies](/content/tumor-targeting-domains-for-chimeric-antigen-receptor-t-cells.html): Bezverbnaya K, Mathews A, Sidhu J, Helsen CW, Bramson JL. Tumor-targeting domains for chimeric antigen receptor T cells. Immunotherapy. 2017 Jan;9(1):33-46. doi: 10.2217/imt-2016-0103. Review. PubMed PMID: 28000526. (77 words, Dec 21, 2016)
- [Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes - Triumvira Immunologics | Engineered T Cell Therapies](/content/viral-engineering-of-chimeric-antigen-receptor-expression-on-murine-and-human-t-lymphocytes.html): Hammill JA, Afsahi A, Bramson JL, Helsen CW. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes. Methods Mol Biol. 2016;1458:137-57. doi: 10.1007/978-1-4939-3801-8_11. PubMed PMID: 27581020. (60 words, Sep 1, 2016)
- [Chimeric antigen receptor-engineered T cells as oncolytic virus carriers - Triumvira Immunologics | Engineered T Cell Therapies](/content/chimeric-antigen-receptor-engineered-t-cells-as-oncolytic-virus-carriers.html): VanSeggelen H, Tantalo DG, Afsahi A, Hammill JA, Bramson JL. Chimeric antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther Oncolytics. 2015 Sep 9;2:15014. doi: 10.1038/mto.2015.14. eCollection 2015. PubMed PMID:27119109; PubMed Central PMCID: PMC4782951. (46 words, Sep 9, 2015)
- [T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice - Triumvira Immunologics | Engineered T Cell Therapies](/content/t-cells-engineered-with-chimeric-antigen-receptors-targeting-nkg2d-ligands-display-lethal-toxicity-in-mice.html): VanSeggelen H, Hammill JA, Dvorkin-Gheva A, Tantalo DG, Kwiecien JM, Denisova GF, Rabinovich B, Wan Y, Bramson JL. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Mol Ther. 2015 Oct;23(10):1600-10. doi: 10.1038/mt.2015.119. Epub 2015 Jun 30. PubMed PMID: 26122933; PubMed Central PMCID: PMC4817919. (62 words, Jul 21, 2015)

## Listings & Categories

- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 9 of 9](/content/author/quik-2025x/page/9/index.html) (103 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 8 of 9](/content/author/quik-2025x/page/8/index.html) (1,144 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 7 of 9](/content/author/quik-2025x/page/7/index.html) (1,233 words)
- [Press Releases & News Archives - Page 7 of 7 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/page/7/index.html) (237 words)
- [Press Releases & News Archives - Page 6 of 7 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/page/6/index.html) (1,080 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 6 of 9](/content/author/quik-2025x/page/6/index.html) (1,256 words)
- [Press Releases & News Archives - Page 5 of 7 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/page/5/index.html) (993 words)
- [Press Releases & News Archives - Page 4 of 7 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/page/4/index.html) (940 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 5 of 9](/content/author/quik-2025x/page/5/index.html) (1,279 words)
- [triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 5 of 5](/content/author/triumvira1/page/5/index.html) (160 words)
- [triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 4 of 5](/content/author/triumvira1/page/4/index.html) (925 words)
- [Press Releases & News Archives - Page 3 of 7 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/page/3/index.html) (1,899 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 4 of 9](/content/author/quik-2025x/page/4/index.html) (1,158 words)
- [Publication Archives - Page 3 of 3 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/publication/page/3/index.html) (160 words)
- [triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 3 of 5](/content/author/triumvira1/page/3/index.html) (752 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 3 of 9](/content/author/quik-2025x/page/3/index.html) (539 words)
- [triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 2 of 5](/content/author/triumvira1/page/2/index.html) (733 words)
- [News Articles Archives - Page 4 of 4 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/news-articles/page/4/index.html) (314 words)
- [News Articles Archives - Page 3 of 4 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/news-articles/page/3/index.html) (492 words)
- [Publication Archives - Page 2 of 3 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/publication/page/2/index.html) (1,491 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 2 of 9](/content/author/quik-2025x/page/2/index.html) (1,003 words)
- [News Articles Archives - Page 2 of 4 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/news-articles/page/2/index.html) (861 words)
- [Press Releases & News Archives - Page 2 of 7 - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/page/2/index.html) (588 words)
- [Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies](/content/author/quik-2025x/index.html) (864 words)
- [Publication Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/publication/index.html) (825 words)
- [Press Releases & News Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/press-releases/index.html) (739 words)
- [News Articles Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/news-articles/index.html) (1,038 words)
- [Events Archives - Triumvira Immunologics | Engineered T Cell Therapies](/content/category/events/index.html) (604 words)
- [triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies](/content/author/triumvira1/index.html) (799 words)

## About Pages

- [Contact - Triumvira Immunologics | Engineered T Cell Therapies](/content/about-us/contact/index.html) (35 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives